Analyst Expectations for Genmab's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Genmab (NASDAQ:GMAB) in the last quarter, with 9 bullish and 8 somewhat bearish ratings. The average 12-month price target for Genmab over the past 3 months is $42.71, which has increased by 22.03% over the past month.
August 15, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings and an increasing price target suggest potential short-term volatility for Genmab.
The mixed analyst ratings indicate differing opinions on the company's performance, which could lead to volatility in the stock price. The increasing price target suggests a positive outlook, but the somewhat bearish ratings indicate potential risks.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100